All Stories

  1. Artificial Intelligence Remote Patient Monitoring for Predicting Overall Survival for Patients Undergoing Radical Cystectomy for Bladder Cancer: Exploratory Analysis of the Prospective Trial
  2. Using an artificial intelligence‐based device to investigate pain outcomes in robotic prostatectomy at low pressure pneumoperitoneum: The RALP clinical trial
  3. The CAMUS Initiative: A Multiphase, Multicentre International Collaboration to Redefine Risk Stratification, Reporting, and Grading of Surgical Complications in Urology
  4. RESECT: A Randomised Controlled Trial of Audit and Feedback in Non–muscle-invasive Bladder Cancer Surgery
  5. Updated Analysis: Blue-Light Transurethral Resection and Biopsy of Bladder Cancer with Hexaminolevulinate in a Single UK Centre
  6. Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study
  7. Training and external validation of machine learning supervised prognostic models of upper tract urothelial cancer (UTUC) after nephroureterectomy
  8. A multi-modal approach for decision making in bladder cancer
  9. Redefining surgical ergonomics: a systematic review of ergonomic outcomes in robotic urological surgery
  10. Clinical Experience with URO17® in the Diagnosis and Surveillance of Bladder Cancer
  11. Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis
  12. Urinary Extracellular Vesicle Signatures as Biomarkers in Prostate Cancer Patients
  13. Kidney-sparing approach for upper tract urothelial carcinoma: An update on current evidence
  14. MP08-02 INVESTIGATING THE RELATIONSHIP BETWEEN CARDIOPULMONARY EXERCISE METRICS AND POST-OPERATIVE OUTCOMES IN RADICAL CYSTECTOMY: INSIGHTS FROM THE IROC PHASE 3 TRIAL
  15. PD08-02 LONG-TERM OUTCOMES OF AQUABLATION FOR BENIGN PROSTATIC HYPERPLASIA: WATER, WATER II, OPEN WATER, FRANCAIS WATER, AND JAPAN PMS STUDIES
  16. AI-powered prostate cancer detection: a multi-centre, multi-scanner validation study
  17. Impact of low-pressure pneumoperitoneum on post-operative pain in robotic urological surgery: a systematic review
  18. Is there a role of PSMA-PET in focal therapy planning and follow-up?
  19. Correction to “How can we reduce morbidity after robot‐assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group”
  20. Optimising prostate biopsies and imaging for the future—a review
  21. 177Lu-PSMA-617 for metastatic prostate cancer in India
  22. National audit of patient reported experience of radical cystectomy for bladder cancer pathways
  23. Impact of NeuroSAFE on Long-Term Outcomes in Robot-Assisted Prostatectomy
  24. Perioperative Blood Transfusion Is Associated with Worse Survival in Patients Undergoing Radical Cystectomy after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
  25. The Oncological and Functional Prognostic Value of Unconventional Histology of Prostate Cancer in Localized Disease Treated with Robotic Radical Prostatectomy: An International Multicenter 5-Year Cohort Study
  26. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non–muscle-invasive Bladder Cancer
  27. Use of mixed gas pneumoperitoneum during minimally invasive surgery: a systematic review of human and mouse modelled laparoscopic interventions
  28. Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
  29. The role of neoadjuvant chemotherapy for patients with variant histology muscle invasive bladder cancer undergoing robotic cystectomy: Data from the International Robotic Cystectomy Consortium
  30. Comparing Gemcitabine and Docetaxel to BCG for High-Risk Bladder Cancer
  31. Is the digital rectal exam any good as a prostate cancer screening test?
  32. The role of URO17® in diagnosis and follow up of bladder cancer patients
  33. Systematic review of the ophthalmic complications of robotic-assisted laparoscopic prostatectomy
  34. The Management of Symptomatic Hydronephrosis in Pregnancy
  35. Comparative study between the use of double J ureteric stents vs bander ureteric stents during robotic-assisted radical cystectomy with intra corporeal ileal conduit urinary diversion
  36. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
  37. Systematic Review of Local Anaesthetic Systemic Toxicity in Urology
  38. Robot-assisted Radical Cystectomy with Orthotopic Neobladder Reconstruction: Techniques and Functional Outcomes in Males
  39. The current use of artificial intelligence in testicular cancer: a systematic review
  40. The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy
  41. Corrigendum to “Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials” [Eur Urol. 2023;84:393–405]
  42. Current practises and the future of robotic surgical training
  43. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials
  44. LBA102 THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received p...
  45. Global Trends of Prostate Cancer by Age, and Their Associations With Gross Domestic Product (GDP), Human Development Index (HDI), Smoking, and Alcohol Drinking
  46. Blue Light Cystoscopy and Bladder Cancer Detection
  47. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort
  48. Comparing Pneumoperitoneum Pressures for Robotic Cystectomy Outcomes
  49. Preclinical Evaluation of Versius Surgical System for Prostate Surgery
  50. Multicentric validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring in two prospective cohorts of patients
  51. Management of urolithiasis in pregnancy
  52. Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer
  53. Applications of artificial intelligence in benign prostatic hyperplasia
  54. TREXIT Catalyst: NHS Prostate Biopsy Data during COVID-19
  55. A Rare Case of Prostatic Stromal Tumour of Uncertain Malignant Potential Surrounding Ejaculatory Ducts in a Patient With Concurrent Prostate Adenocarcinoma
  56. A North-West London Experience of the Impact of Treatment Related Toxicity on Clinical Outcomes of Elderly Patients with Germ Cell Tumors
  57. A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond
  58. The increasing indications of FDG-PET/CT in the staging and management of Invasive Bladder Cancer
  59. Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer
  60. Corrigendum to “Nomogram Predicting Bladder Cancer–specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium” [Eur Urol Focus 2021;7:1347–54]
  61. Single tertiary cancer center experience on the management of pT3b prostate cancer after robotic-assisted laparoscopic prostatectomy
  62. 254 Driving Improvement for Testicular Cancer Patients within a Urology Unit at a District General Hospital
  63. Distribution of surgical smoke particles within a simulated laparoscopic cavity utilizing an AirSeal® system
  64. Evaluation of prognostic risk models for postoperative pulmonary complications in adult patients undergoing major abdominal surgery: a systematic review and international external validation cohort study
  65. Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer
  66. Groin pain in the postradiotherapy pelvis: have you considered osteomyelitis?
  67. Findings in 1,123 Men with Preoperative 68 Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally ...
  68. Methods of Sentinel Lymph Node Detection and Management in Urinary Bladder Cancer—A Narrative Review
  69. A multicenter real-life U.K. study of use of immunotherapeutic agents in metastatic urothelial cancer.
  70. Clinical outcomes of low-pressure pneumoperitoneum in minimally invasive urological surgery
  71. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer
  72. Correction to: Neurovascular structure-adjacent frozen-section examination robotic-assisted radical prostatectomy: outcomes from 500 consecutive cases in the UK
  73. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
  74. Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic
  75. Nomogram Predicting Bladder Cancer–specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium
  76. Neurovascular structure-adjacent frozen-section examination robotic-assisted radical prostatectomy: outcomes from 500 consecutive cases in the UK
  77. Biomarkers in Bladder Cancer Surveillance
  78. A systematic review and meta-analysis of post-operative urinary retention with anaesthetic and analgesic modalities
  79. The Scottish Bladder Cancer Quality Performance Indicators Influencing Outcomes, Prognosis, and Surveillance (Scot BC Quality OPS) Clinical Project
  80. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer
  81. Prostate cancer and microfluids
  82. Artificial intelligence in urological oncology: An update and future applications
  83. Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer—A Systematic Review and Meta-Analysis
  84. Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes
  85. Serum cytokine levels as markers of paralytic ileus following robotic radical prostatectomy at different pneumoperitoneum pressures
  86. Robotic Cystectomy: Increasing Trends and Postoperative Complications in England from 2013 to 2019
  87. Major Urological Cancer Surgery for Patients is Safe and Surgical Training Should Be Encouraged During the COVID-19 Pandemic: A Multicentre Analysis of 30-day Outcomes
  88. Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma
  89. Guideline of guidelines: Muscle-invasive bladder cancer
  90. Has robotic prostatectomy determined the fall of the laparoscopic approach?
  91. Urinary biomarkers in bladder cancer: A review of the current landscape and future directions
  92. Urinary biomarkers to mitigate diagnostic delay in bladder cancer during the COVID-19 era
  93. Review of the evidence for robotic-assisted robotic cystectomy and intra-corporeal urinary diversion in bladder cancer
  94. Technical caveats in salvage robot assisted radical prostatectomy
  95. The Emerging Role of Artificial Intelligence in the Fight Against COVID-19
  96. Real-time assessment of learning curve for robot-assisted laparoscopic prostatectomy
  97. The role of URO17™ biomarker to enhance diagnosis of urothelial cancer in new hematuria patients—First European Data
  98. LBA83 Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: A multi-centre North London experience
  99. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer
  100. Robot-assisted vs open radical cystectomy for bladder cancer in adults
  101. Does neuroendocrine like tumor pathology impact neoadjuvant chemotherapy response precystectomy
  102. The clinical and financial implications of a decade of prostate biopsies in the NHS: analysis of Hospital Episode Statistics data 2008–2019
  103. Outcomes of the 2019 Novel Coronavirus in patients with or without a history of cancer - a multi-centre North London experience
  104. Robot-assisted laparoscopic prostatectomy: How can we get better?
  105. A Comparison of Urology Training Across Five Major English-Speaking Countries
  106. Is Non-Chlamydial Non-Gonococcal Urethritis Associated with Significant Clinical Complications in Men? A Systematic Review
  107. Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience
  108. Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers
  109. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy
  110. Incidental Lymphoplasmacytic Lymphoma Diagnosed Following Robotic-Assisted Laparoscopic Prostatectomy for Prostate Cancer
  111. The Lister AirSeal® port closure technique – Initial patient outcomes
  112. The role of extended venous thromboembolism prophylaxis for major urological cancer operations
  113. Somatic Transformation in Metastatic Testicular Germ Cell Tumours – A Different Disease Entity
  114. Haematuria
  115. Radical cystectomy complications and perioperative mortality
  116. A single center experience of the impact of treatment-related toxicity in the clinical outcomes of elderly patients with metastatic germ cell tumors.
  117. Robotic versus open radical cystectomy for bladder cancer in adults
  118. Detection rates of recurrent prostate cancer: 68Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET/CT scans. A systematic review
  119. Is it oncologically and clinically safe to adopt a bladder sparing approach in complete responders following neoadjuvant chemotherapy alone without proceeding to a radical cystectomy?
  120. T1G3 bladder cancer, bacillus Calmette-Guerin and radical cystectomy: continued debate
  121. Does the robot have a role in radical cystectomy?
  122. Avoiding the Obturator Jerk during TURBT
  123. Single-centre Experience of Use of Radium 223 with Clinical Outcomes Based on Number of Cycles and Bone Marrow Toxicity
  124. The future of robotic surgery
  125. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy
  126. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy
  127. EP-1552: Single centre experience of the use of Radium-223 with clinical outcomes based on number of cycles
  128. Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis
  129. Prevalence of haptic feedback in robot-mediated surgery: a systematic review of literature
  130. The neurovascular structure‐adjacent frozen‐section examination (Neuro SAFE ) approach to nerve sparing in robot‐assisted laparoscopic radical prostatectomy in a British setting – a prospective observa...
  131. Atypical Small Acinar Proliferation and High Grade Prostatic Intraepithelial Neoplasia: Should We Be Concerned? An Observational Cohort Study with a Minimum Follow-Up of 3 Years
  132. Can Anterior Prostatic Fat Harbor Prostate Cancer Metastasis? A Prospective Cohort Study
  133. Early vs. standard unclamping technique in minimal access partial nephrectomy: a meta-analysis of observational cohort studies and the Lister cohort
  134. The Management of Unplanned Erection during Endoscopic Urological Surgery
  135. How to write a systematic review: Tips and tricks for surgeons in training
  136. The association of level of practical experience in transrectal ultrasonography guided prostate biopsy with its diagnostic outcome
  137. External validation of four nephrometry scores for trans-peritoneal robotic partial nephrectomy
  138. Haematuria
  139. The Role of Positron Emission Tomography With 68Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatec...
  140. Intraoperative Frozen Section of the Prostate Reduces the Risk of Positive Margin Whilst Ensuring Nerve Sparing in Patients with Intermediate and High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy: First Reported UK Series
  141. Spinal Anesthesia Facilitates the Early Recognition of TUR Syndrome
  142. Bilateral obstruction of bilaterally duplicated collecting systems requiring upper and lower moiety drainage
  143. MP19-02 EXTERNAL VALIDATION OF FOUR NEPHROMETRY SCORES FOR TRANS-PERITONEAL ROBOTIC PARTIAL NEPHRECTOMY-DO WE HAVE A WINNER?
  144. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?
  145. Effect of Pneumoperitoneum on Renal Function and Physiology in Patients Undergoing Robotic Renal Surgery
  146. Post-Operative Pain Management in Patients Undergoing Robotic Urological Surgery
  147. Robotic Partial Cystectomy for Primary Urachal Adenocarcinoma of the Urinary Bladder
  148. Editorial Comment to Validation of an educational program balancing surgeon training and surgical quality control during robot‐assisted radical prostatectomy
  149. Robot-Assisted Laparoscopic Bladder Diverticulectomy and Ureteral Re-Implantation for a Diverticulum Containing High Grade Transitional Cell Carcinoma
  150. Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice
  151. Evolving role of positron emission tomography (PET) in urological malignancy
  152. Immunotherapy for bladder cancer
  153. MP65-06 A MULTI-INSTITUTIONAL ANALYSIS OF OUTCOMES IN PATIENTS WITH CLINICALLY NODE POSITIVE UROTHELIAL BLADDER CANCER TREATED WITH INDUCTION CHEMOTHERAPY AND RADICAL CYSTECTOMY
  154. PD41-05 FINAL PATHOLOGIC STAGE AFTER NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY FOR BLADDER CANCER: DOES PT0 PREDICT BETTER SURVIVAL THAN PTA/PTIS/PT1?
  155. MP72-15 THE INTERVAL BETWEEN DIAGNOSIS AND RADICAL CYSTECTOMY DOES NOT IMPACT THE OUTCOMES OF PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY
  156. Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
  157. A Prospective Randomised Paired Trial of Sirolimus versus Tacrolimus as Primary Immunosuppression following Non-Heart Beating Donor Kidney Transplantation
  158. Robotic pyeloplasty: Initial experience of a single UK centre
  159. Robotic partial nephrectomy: our first 30 consecutive cases
  160. Cardiopulmonary exercise testing in patients undergoing radical cystectomy (open, laparoscopic and robotic)
  161. MP55-08 PATHOLOGIC RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN A MULTICENTRE COHORT OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER.
  162. A rare aetiology for increased drain output following a robotic-assisted prostatectomy
  163. Robotic versus traditional laparoscopic partial nephrectomy: comparison of outcomes with a transition of techniques
  164. Cerebral astroblastoma
  165. Robotic Prostatectomy Has a Superior Outcome in Larger Prostates and PSA Density Is a Strong Predictor of Biochemical Recurrence
  166. Second-line chemotherapy for advanced bladder cancer: A survey of current UK practice
  167. Can the Leibovich score for clear cell renal cell carcinoma ( ccRCC ) be accurately reported by a general pathologist?
  168. Can the R.E.N.A.L Nephrometry Score Preoperatively Predict Postoperative Clinical Outcomes in Patients Undergoing Open and Laparoscopic Partial Nephrectomy?
  169. The prognostic value of transrectal ultrasound guided biopsy in patients over 70 years old with a prostate specific Antigen (PSA) level ≤15 ng/ml and normal digital rectal examination: A 10-year prospective follow-up study of 427 consecutive patients
  170. The surgical management and prognosis of renal cell cancer with IVC tumor thrombus: 15-Years of experience using a multi-specialty approach at a single UK referral center
  171. “The Lister Technique”: a new technique for the management of the distal ureter during radical robotic nephroureterectomy
  172. Oncological outcomes in low-, intermediate- and high D'Amico-risk patients undergoing laparoscopic radical prostatectomy at a single UK centre
  173. Should the presence of a culture positive urinary tract infection exclude patients from rapid evaluation hematuria protocols?
  174. Is it still clinically and economically viable in the UK to prescribe vacuum erection devices for patients with erectile dysfunction after radical prostatectomy?
  175. Discontinuation rates and inter‐injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity
  176. Impaired cardiopulmonary reserve in an elderly population is related to postoperative morbidity and length of hospital stay after radical cystectomy
  177. 515 IMPAIRED CARDIOPULMONARY RESERVE IN AN ELDERLY POPULATION IS RELATED TO POSTOPERATIVE MORBIDITY AND HOSPITAL LENGTH OF STAY AFTER RADICAL CYSTECTOMY
  178. 1214 ONCOLOGICAL OUTCOMES IN LOW, INTERMEDIATE AND HIGH D'AMICO RISK PATIENTS UNDERGOING LAPAROSCOPIC RADICAL PROSTATECTOMY AT A SINGLE UK CENTRE
  179. 2216 THE ASSOCIATION OF THE DIAGNOSTIC OUTCOME OF THE TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY WITH THE OPERATOR EXPERIENCE: IMPLICATIONS FOR TRAINING
  180. Developing a Robotic Prostatectomy Service and a Robotic Fellowship Programme - Defining the Learning Curve
  181. Urinary function and health-related quality of life of patients after laparoscopic radical prostatectomy: two methods of assessment for 112 patients with up to six years of follow-up
  182. Classification, epidemiology and therapies for testicular germ cell tumours
  183. Continent Urinary Diversion
  184. Hematuria Secondary to Benign Prostatic Hyperplasia: Retrospective Analysis of 166 Men Identified in a Single One Stop Hematuria Clinic
  185. Metabolic complications of urinary intestinal diversion
  186. Robotic Intracorporeal Ileal Conduit Formation: Initial Experience from a Single UK Centre
  187. Editorial Comment to Robotic versus laparoscopic partial nephrectomy for tumor in a solitary kidney: A single institution comparative analysis
  188. Renal denervation for treatment-resistant hypertension
  189. The Clinical Effectiveness of Intravesical Sodium Hyaluronate (Cystistat®) in Patients with Interstitial Cystitis/Painful Bladder Syndrome and Recurrent Urinary Tract Infections
  190. The Acute Pediatric Scrotum: Presentation, Differential Diagnosis and Management
  191. "Is partial cystectomy an oncologically viable option for primary urachal adenocarcinoma?"
  192. Bladder Cancer Diagnosis and Identification of Clinically Significant Disease by Combined Urinary Detection of Mcm5 and Nuclear Matrix Protein 22
  193. Developing a Laparoscopic Radical Prostatectomy Service: Defining the Learning Curve
  194. Therapeutic kidney donation: a potential source of precious organs
  195. 1784 “THE IMPACT OF EARLY RE-RESECTION ON UPSTAGING AND UPGRADING IN PATIENTS WITH HIGH GRADE NON-MUSCLE INVASIVE BLADDER CANCER”
  196. 1419 IS CONCOMITANT CARCINOMA IN SITU A RELATIVE CONTRAINDICATION TO NEOADJUVANT CHEMOTHERAPY FOR MUSCLE INVASIVE TCC BLADDER?
  197. Current Strategies to Enhance Recovery following Radical Cystectomy: Single Centre Initial Experience
  198. Hyperammonaemic encephalopathy secondary to an infected perinephric urinoma
  199. The modified Barry technique to prevent vesicoureteric reflux in paediatric renal transplant recipients: Initial recipient outcomes
  200. A Retrospective Audit of 381 Cases of Hypospadias Correction in a Regional Paediatric Surgery Centre
  201. Renal Infarction Secondary to Anabolic-Androgenic Steroids Abuse
  202. THE DEVELOPING CONCEPT OF USING ELECTIVE BENIGN AND MALIGNANT KIDNEYS FOR RENAL TRANSPLANTATION
  203. Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
  204. Esophageal tuberculosis: role of endoscopic ultrasound in diagnosis
  205. The Role of Early Re-Resection in pTaG3 Transitional Cell Carcinoma of the Urinary Bladder
  206. The Successful Urological Management of Self-Injection of Petroleum Distillate (WD40 TM) to the Scrotum
  207. Radical renal surgery (laparoscopic and open) in octogenarians
  208. Are Saturation Biopsies of the Prostate Essential?
  209. 155 DIAGNOSIS OF BLADDER CANCER BY COMBINED DETECTION OF MINICHROMOSOME MAINTENANCE 5 PROTEIN AND NMP22 IN URINE
  210. 318 THE IMPACT OF EARLY RE-RESECTION ON UPSTAGING AND UPGRADING ON RECURRENCES IN PATIENTS WITH HIGH GRADE NON-MUSCLE INVASIVE BLADDER CANCER
  211. Laparoscopic partial nephrectomy: Technical considerations and an update
  212. The Physiological and Anesthetic Considerations in Octogenarians Undergoing Laparoscopic Radical Nephrectomy
  213. An Evaluation of Current Surgical Techniques Used for Vesicoureteric Anastomosis in Paediatric Renal Transplantation in the United Kingdom
  214. 735 AN EVALUATION OF CURRENT SURGICAL TECHNIQUES USED FOR VESICOURETERIC ANASTOMOSIS IN PAEDIATRIC RENAL TRANSPLANTATION IN THE UNITED KINGDOM: A NATIONALAND REGIONAL PERSPECTIVE
  215. Rapid Metastasis to the Scrotum and Penis following Laparoscopic Radical Cystoprostatectomy
  216. Commentary to “Pediatric hemorrhagic cystitis” by Decker DB, Karam JA, Wilcox DT. J Pediatr Urol 2009;5:254–264
  217. The surgical management of the refractory overactive bladder
  218. Autoimmune Clinical Manifestations following Intravesical Bacillus Calmette-Guérin and Interferon alpha 2b Immunotherapy for Superficial Bladder Cancer
  219. Neonatal urinary ascites secondary to urinary bladder rupture
  220. Benign Fibroepithelial Polyp of Renal Pelvis in a Patient with Familial Adenomatous Polyposis: A Successful Percutaneous Nephroscopic Management Strategy
  221. A Rare and Serious Complication of Elective Suprapubic Catheter Change
  222. Prevention and management of BK‐virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation – a systematic review and evidence‐based guidance for clinical management
  223. Mixed Epithelial and Stromal Tumor of the Kidney: A Rare Variant and Review of Current Literature
  224. 289: Does Prior Exposure Affect Response to Intravesical BCG and Interferon Alpha Immunotherapy for Superficial Bladder Cancer?
  225. ecancermedicalscience
  226. ecancermedicalscience